financetom
Business
financetom
/
Business
/
Japan e-comics platform Infocom to decide on Blackstone takeover offer
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Japan e-comics platform Infocom to decide on Blackstone takeover offer
Jun 17, 2024 8:49 PM

TOKYO, June 18 (Reuters) - Japanese digital comic

distributor Infocom ( IFFOF ) will announce its board's decision

on a takeover bid from Blackstone once all its disclosure

documents are ready, the company said on Tuesday.

Infocom ( IFFOF ) was responding to a report in the Nikkei newspaper

that Blackstone had reached a final agreement to acquire

Infocom ( IFFOF ), priced at around 6,000 yen per share for a total

purchase price of around 280 billion yen ($1.78 billion). The

deal would take effect on Wednesday, it added.

Blackstone declined to comment on the deal.

Infocom ( IFFOF ) operates digital comic site MechaComic, which is

Japan's largest, according to its Twitter page.

Global investor interest in Japanese companies has surged in

recent years as the weak yen, strong public markets and

corporate governance changes make mergers and acquisitions (M&A)

attractive.

M&A in Japan reached a record $35.5 billion in 2023, LSEG

data shows, and this deal would be Blackstone's largest

acquisition in Japan, the Nikkei said.

Infocom's ( IFFOF ) share price has more than doubled since news of

the potential buyout was first reported last month, rising to

above 6,000 yen on Tuesday from below 3,000 yen in early May.

Infocom's ( IFFOF ) current parent company, Teijin ( TINLF ), will not

take part in the takeover bid but will sell all the 55% of

Infocom's ( IFFOF ) shares that it owns in a share buyback after the

buyout is completed, the Nikkei reported.

Infocom ( IFFOF ), which is currently listed on the Tokyo Stock

Exchange Prime market, will go private if the deal goes ahead,

the Nikkei added.

($1 = 157.5300 yen)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Klarna Completes Initial Public Offering
Klarna Completes Initial Public Offering
Sep 11, 2025
LONDON--(BUSINESS WIRE)-- Klarna Group plc ( KLAR ) (“Klarna”), the global digital bank and flexible payments provider, announced today the closing of its initial public offering of 34,311,274 ordinary shares, of which 5,000,000 ordinary shares were sold by Klarna ( KLAR ) and 29,311,274 ordinary shares were sold by certain selling shareholders, at a public offering price of $40.00 per...
Klarna Completes Initial Public Offering
Klarna Completes Initial Public Offering
Sep 11, 2025
LONDON--(BUSINESS WIRE)-- Regulatory News: Klarna Group plc ( KLAR ) (“Klarna”), the global digital bank and flexible payments provider, announced today the closing of its initial public offering of 34,311,274 ordinary shares, of which 5,000,000 ordinary shares were sold by Klarna ( KLAR ) and 29,311,274 ordinary shares were sold by certain selling shareholders, at a public offering price of...
What's Going On With Galaxy Digital (GLXY) Stock Today?
What's Going On With Galaxy Digital (GLXY) Stock Today?
Sep 11, 2025
Galaxy Digital Inc ( GLXY ) shares are trading higher Thursday. The company has made recent strategic announcements that strengthen its institutional footprint in Asia and develop new pathways for digital securities. What To Know: On Wednesday, the firm announced its GK8 subsidiary will provide custody technology for BDACS, a South Korean regulated institutional digital asset custodian. The partnership will...
AbbVie shares hit record high as key immunology drug set for exclusivity until 2037
AbbVie shares hit record high as key immunology drug set for exclusivity until 2037
Sep 11, 2025
(Reuters) -AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a four-year extension, according to some analysts. Rinvoq, used for the treatment of rheumatoid arthritis and other autoimmune diseases, is AbbVie's second best-selling drug behind Skyrizi. The company has been doubling...
Copyright 2023-2026 - www.financetom.com All Rights Reserved